Related Experiment Video
Updated: Oct 4, 2025
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.7K
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource
Véronique Ouellet1, Andrew Erickson2,3,4,
1Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.
Summary
Researchers created unique prostate cancer tissue microarrays (TMA) to understand diverse patient outcomes. This Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) resource aids biomarker validation for improved treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Prostate cancer outcomes vary significantly, necessitating research into molecular underpinnings.
- Understanding this heterogeneity is a key priority for Movember.
- The Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project was initiated to address this challenge.
Purpose of the Study:
- To construct and provide a comprehensive resource of annotated prostate cancer tissue microarrays (TMA).
- To facilitate biomarker validation for predicting disease progression and treatment response.
- To investigate molecular differences in primary tumors, lymph node metastases, and castration-resistant prostate cancer (CRPC).
Main Methods:
- Development of three distinct TMA sets (TMA1, TMA2, TMA3) from prostate cancer samples.
- Collection of samples from multiple global institutions.
- Rich clinical annotation of all tissue specimens.
Main Results:
- Successful creation of the GAP1-UTMA project, comprising tissue specimens from 501 prostate cancer patients.
- Detailed characterization of TMA1 for validating biomarkers related to lymph node metastasis and progression.
- TMA2 designed to study castration-resistant prostate cancer (CRPC) and response to androgen deprivation therapy (ADT).
- TMA3 established to assess molecular marker heterogeneity in lethal prostate cancer metastases across different anatomical sites.
Conclusions:
- The GAP1-UTMA project has generated a valuable, well-annotated resource for the prostate cancer research community.
- This resource is available for biomarker validation to address critical clinical questions.
- It will aid in understanding disease progression and optimizing treatment strategies.
